Mannkind (MNKD) Current Deferred Revenue (2014 - 2026)
Mannkind (MNKD) reported Current Deferred Revenue of $11.5 million for Q1 2026, down 1.97% year-over-year from $11.8 million in Q1 2025, and down 24.83% on a QoQ basis from $15.3 million in Q4 2025.
Mannkind (MNKD) has 13 years of Current Deferred Revenue data on file, last reported at $11.5 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 1.97% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 1.97% YoY) and the FY2025 annual result came in at $15.3 million, up 23.57% from the prior year.
- Current Deferred Revenue slipped to $11.5 million in Q1 2026 per MNKD's latest filing, from $15.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $78.9 million in Q4 2023 and bottomed at $1.3 million in Q1 2022.
- The 5-year median for Current Deferred Revenue is $10.1 million (2025), against an average of $19.1 million.
- The widest annual swing landed in 2022, when Current Deferred Revenue tumbled 94.95%; it then jumped 5829.61% in 2023.
- Tracing MNKD's Current Deferred Revenue over 5 years: stood at $63.6 million in 2022, then climbed by 24.09% to $78.9 million in 2023, then sank by 84.27% to $12.4 million in 2024, then gained by 23.57% to $15.3 million in 2025, then fell by 24.83% to $11.5 million in 2026.
- Per Business Quant, the three latest MNKD Current Deferred Revenue figures stand at $11.5 million (Q1 2026), $15.3 million (Q4 2025), and $10.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.53 Mn |
| Dec 31, 2025 | 15.33 Mn |
| Sep 30, 2025 | 10.12 Mn |
| Jun 30, 2025 | 10.95 Mn |
| Mar 31, 2025 | 11.76 Mn |
| Dec 31, 2024 | 12.41 Mn |
| Sep 30, 2024 | 6.52 Mn |
| Jun 30, 2024 | 7.42 Mn |
| Mar 31, 2024 | 7.60 Mn |
| Dec 31, 2023 | 78.88 Mn |
| Sep 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 3.49 Mn |
| Mar 31, 2023 | 77.50 Mn |
| Dec 31, 2022 | 63.57 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Dec 31, 2021 | 20.37 Mn |
| Sep 30, 2021 | 14.02 Mn |
| Jun 30, 2021 | 20.13 Mn |
| Mar 31, 2021 | 25.88 Mn |
| Dec 31, 2020 | 34.94 Mn |
| Sep 30, 2020 | 28.87 Mn |
| Jun 30, 2020 | 32.18 Mn |
| Mar 31, 2020 | 30.84 Mn |
| Dec 31, 2019 | 40.85 Mn |
| Sep 30, 2019 | 32.21 Mn |
| Jun 30, 2019 | 32.37 Mn |
| Mar 31, 2019 | 32.38 Mn |
| Dec 31, 2018 | 47.57 Mn |
| Sep 30, 2018 | 3.60 Mn |
| Jun 30, 2018 | 2.69 Mn |
| Mar 31, 2018 | 2.30 Mn |
| Dec 31, 2017 | 750,000.00 |
| Sep 30, 2017 | 3.02 Mn |
| Jun 30, 2017 | 2.59 Mn |
| Mar 31, 2017 | 1.84 Mn |
| Dec 31, 2016 | 1.00 Mn |
| Sep 30, 2016 | 2.01 Mn |
| Jun 30, 2016 | 26.88 Mn |
| Mar 31, 2016 | 17.68 Mn |
| Dec 31, 2015 | 17.50 Mn |
| Sep 30, 2015 | 17.47 Mn |
| Jun 30, 2015 | 13.40 Mn |
| Mar 31, 2015 | 7.05 Mn |
| Dec 31, 2014 | 196.97 Mn |
| Sep 30, 2014 | 150.00 Mn |